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with general impact on cell growth control and tumor progression.
Therefore, we studied a tumor cell line, HTZ-19, which was derived
from a human melanoma central nervous system metastasis of a
patient with prolonged tumor-free intervals. FITZ-19 cells, cultured
under serum-free conditions, produced melanin and were shown to
express bFGF, PDGF-A, TGF-@31,and TGF-@32,as well as several
other, potentially tumor progression associated-proteins, including
diazepam-binding inhibitor and tissue inhibitor of metalloprotein
ases-2 (5â€”7).Although HTZ-19 cells secrete a number of positive
autocrine growth-regulatory proteins, we identified a new potent MIA
from supernatants of this cell line that might explain its exceptionally
slow tumor progression in vivo (8).
We now report the molecular cloning of this novel growth-regula
tory protein and compare its sequence obtained from human and
mouse cDNA libraries. Malignant melanoma is the neoplasm with the
largest increase in incidence over the past years (9). A growth
inhibitory protein like MIA may, therefore, play a significant role in
cancer therapy. For this approach, we have expressed and purified MIA
using both prokaryotic and eukaryotic expression vectors and provided a
preliminary functional characterization of the recombinant protein.
MATERIALS AND METHODS
Cell Lines, Tissue Culture, and Proliferation Assays. All melanomacell
lines were grown in Ham's F-l2lDulbecco's modified Eagle's medium sup
plemented with 10% FCS as monolayers under standard culture conditions, as
described (8). HTZ-1014, HTZ-1004, HTZ-320, and HTZ-318 were estab
lished from human malignant melanoma central nervous system tumor metes
tases; G-361 (CRL 1424) and SK-Mel 3 (HTB-69) were obtained from
American Type Culture Collection, and Mel Im was a gift from R. Riethmllller
and J. Johnson, Munich, Germany. HTZ-19 cells were grown in serum-free
medium. H-36 human fibroblasts were grown from normal human skin biop
sies and were kindly provided by the Department of Human Genetics, Uni
versity of Wurzburg,, Wurzburg, Germany. The glioma cell lines HTZ-17,
HTZ-146, HTZ-298 (glioblastoma multiforme), HTZ-262, and HTZ-243 (ana
plastic astrocytoma, WHO grade III) were established from human tumor
biopsies and grown in Dulbecco's modified Eagle's medium-10% fetal calf
serum as standard monolayer cultures (6, 10). PA-i human teratocarcinoma
cells were obtained from the American Type Culture Collection (CRL 1572)
and were grown in minimal essential medium-10% FCS. The subclone 9117
used in this study and a detailed transfection protocol using calcium phosphate
precipitationhave been described(11). Peripheralblood mononuclearcells
were separated by Ficoll-Hypaque gradient centrifugation of venous blood
received from healthy donors (12).
[3H]Thymidine incorporation was measured as described (8). For growth
curves, 2 X 10' cells were seeded into 24-well dishes (Nunc, Roskilde,
Denmark), and the number of viable cells was counted daily. Duplicates were
treated in parallel with medium supplemented with recombinant MIA or
control purificate (see below). The viability of cells was confirmed by trypan
blue exclusion. For dose-response curves, cells were counted only on day 5.
Purification ofMIA from HTZ-19 Supernatant& A detailed protocol for
the recovery of the HTZ-i9 conditioned tissue culture supernatant and purifi
cation of MIA has been described previously (7, 8). Briefly, S liters of
supernatants were concentrated by membrane ultrafiltration (YM-2 membrane
cutoff, Mr 2,000; Amicon, Danvers, MA), and the retentate was dialysed
against 0.1 M acetic acid. The protein concentrate was cleared by ultracentrif
ugation (28,000 rpm; Ti 60 rotor; Beckmann, Munich, Federal Republic of
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ABSTRACT
Growth and progression of malignant melanoma cells Is Influenced by
a complex network of growth-stimulating and -Inhibiting factors pro
duced by both the tumor cells and the local environment Here we report
the purification and molecular cloning of a novel growth regulating
protein, designated melanoma Inhibitory activity (MIA) and provide a
preflinbanry fUnctional characterIzatIon. MIA Is translated as a 131-amino
add precursor and processed into a mature 107-amino acid protein after
cleavage eta putative secretion signaL A murine complementary DNA was
isolated that encoded a MIA-protein with 88% amino add Identity. MIA
Is secreted Into the culture supernatant by several malignant melanoma
cell lines as an Mr 11,000 autocrine growth factor and acts as a potent
tumor cell growth Inhibitor for malignant melanoma cells and some other
neuroectodermal tumors, including gliomas. MIA has no homology to any
other known protein and, therefore, represents a novel type of growth
regulatory factor. Furthermore, we describe a molecular approach to
exprean fUnctionally active MIA in Escherichia coli, which might be
attractive M a Ititure antitumor therapeutical substance.
INTRODUCTION
Tumorgrowthand proliferationis regulatedby a complex network
of different growth factors, which play critical roles in tumorigenesis,
invasion, and tumorprogression.Growth-regulatoryfactors are pro
duced by either the environment or by the tumor and may control
cellular functions in an autocrine and paracrine manner. Melanoma
cells have been shown to produce TGF7-a, TGF-@1, TGF-@32,TGF
@33,PDGF-A, PDGF-B, melanoma growth stimulating activity
(MGSA), bFGF, IL-la and IL-1@3,IL-6, IL-8, and tumor necrosis
factor a (1, 2); however, malignantprogressionof melanomacells is
accompanied by a successive decline in exogenous growth factor
requirements (3). The purification and molecular cloning of these
factors have provided new insights into tumor pathophysiology and,
possibly, new targets for antitumor therapy.
Whereas most melanomas that have progressed to widespread
metastatic disease relapse very soon after therapeutic intervention,
rare cases of spontaneous, prolonged tumor-free survival have been
reported (reviewed in Ref. 4). A molecular understanding of tumor
growth regulation in these cases might reveal key regulatory factors
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Germany) and separated by BioGel P-1O (Bio-Rad, Richmond, CA) gel per
meation chromatography in 1 M acetic acid. Fractions 39â€”45,containing the
highest specific biological activity as determined by [3H]thymidine incorpo
ration, were pooled (P-b pool) and lyophilized again. After solubilization in
0.1% TFA, proteins were further separated by rpHPLC on a MinoRPC column
(Pharmacia, Freiburg, Federal Republic of Germany). Proteins were eluted
with a three-step gradient: 2â€”25%solvent B within 5 mm, 25â€”50%solvent B
within 120 mm, and 50â€”100% within 5 mm. Solvent A was 0.1% TFA, and
solvent B was 80% acetonitrile-0.056% TFA. Gradient was started 5 mm after
probe injection (100 ,.@gP-10 pool).
Protein Sequence Analysis. The rpHPLC fraction 42 exhibited the highest
biological activity and was used for sequence analysis after drying under
vacuum. Protein sequencing was performed on an Applied Biosystems 477 A
gas-phase sequencer (Boulder, CO) that was equipped with a i20-APTH
analyzer. After determination of the NH2-terminal sequence, the protein was
dissolved in 8 Murea-0.4 MNH4HCO3 (pH 7.9) and 5 pi-45 mM dithiothreitol
and incubated for 15 mm at 50Â°C.After the addition of 5 @tl-i00mi@i
iodacetamide and incubation for 15 min at room temperature, either trypsin or
Asp-N proteaseswere added in 140 gtlH20 (0.003 units of enzyme/mgprotein),
and digestions were performed for 24 h at 37Â°C.The resulting peptides were
separatedon a Vydac C182.1 x 250 mm rpHPLCcolumn by a gradientof buffer
A (0.06% TFA in H20) and buffer B (0.052% TFA-80% acetonitrile).Three
gradient steps were performed: 2-40% buffer B within 60 mm, 40-75% buffer B
within 30 mm, and 75-98% buffer B within iS min at a flow rate of 02 mI/mm.
Finally, the peptideswere subjectedto NH2-terminalsequencing.
Isolation of Recombinant cDNA Clones. For reverse transcriptase-po
lymerase chain reaction amplification of a partial MIA cDNA, the primers
UP-i (5'-TGT GAA TfC AAG 111 AITC/GI GCI GAC/T CAA/G GANG
TG- 3') and DP-i (5'TGT GTC GAC TOT TCGTAG AAA/G TCC CAC/T
TFG/A TC-3') were used matching amino acid residues 34â€”41and 131â€”124
of the MIA protein, as predicted from microsequenced peptides. Restriction
sites EcoRI and Sal!, added for convenient subcloning, are underlined. First
strand cDNA was synthesized with murine Moloney leukemia virus-reverse
transcriptase using 0.5 @gDP-i and 10 @gHTZ-19 RNA, according to a
protocol that was described previously (13), and cDNA was amplified by 32
cycles using the following temperature profile: 1 mm at 95Â°C,1 min at 55Â°C,
and 0.5 mm at 72Â°C.The amplified product was subcloned into the vector
pBluescnpt (Stratagene, La Jolla, CA) and verified by sequencing as a partial
MIA cDNA clone that encoded all of the 85 amino acids obtained from peptide
sequencing. The insert was then used as a radiolabeled probe (14) to screen
300,000 recombinant plaques from a HTZ-i9 cDNA library in the phage
Agti1. Handling of phages, plaque lifting, screening, and Southern hybridiza
tions were performed according to standard protocols (15). Ten positive and
independently derived plaques were purified; then the inserts were subcloned
into the plasmid pBluescript sequenced on both strands. The longest cDNA
insert, huMIA-7, (Fig. 2c) was used to screen 300,000 plaques from a com
mercially available murine embryo cDNA library (Novagen, Madison, WI;
embryo day 13.5), resulting in 5 recombinant clones with overlapping cDNA
inserts. The inserts were recovered using CRE-loxP-mediatedplasmid excision
and fully sequenced on both strands. Sequencing was performed in part
according to the standard Sanger protocol (16) and in part by cycle sequencing
using an automatic DNA sequencer (Applied Biosystems).
Northern Blots. RNA was isolated as described (17). Total cellular RNA
(20 pg/lane) was loaded on a 1% formaldehyde-agarose gel and transferred to
nylon membranesaccordingto a standardprotocol (15). The completehuMIA-7
cDNA insert was radioactivelylabeled (14) and used as a probe. Final washes
wereperformedin 1 X Standardsaline-citrate(0.i5 MNaC1,0.15Msodiumcitrate)
for two times for 1 h each at 68Â°C.
Preparation of Antisera and Western Blots. For preparation of antisera,
a peptide corresponding to MIA amino acids 4â€”18of the mature peptide was
synthesized and coupled via a COOH-terminal cysteine residue to bovine
serum albumin using (m-maleimidobenzoic acid-N-hydroxysuccinimide ester)
as a bifunctional reagent (18). Rabbits were immunized by three s.c. injections.
Supernatants for Western blotting were prepared as described above. SDS
PAGE and Western transfersto nitrocellulosemembraneswere performed
according to the method of Kyse-Anderson (19). After blocking with ovalbu
mm, blots were incubated for 2 h with antisera diluted 1:50 in TBST (Tris
buffered saline with 0.05% Tween 20). Washing of blots was followed by
incutbation with a second alkaline phosphatase-conjugated mouse anti-rabbit
antibody. For color development, 5-bromo-4-chloro-3-indolyl phosphate/nitro
blue tetrazolium substrate was used.
Expression and Pudflcation of Recombinant Protein. Escherichia coli
M15(pREP4) cells carrying the DHFR-MIA fusion protein expression plasmid
pOE 40-MIA were grown to an absorbance of OD@ = 0.6 and induced by 1
mM isopropyl-1-thio-j3-D-galactopyranosidefor 4 h and lysed by sonication.
The soluble protein fraction was subjected to nickel-ion metal chromatography
as described in detail elsewhere (13). The fused DHFR-MIA proteins, linked
by a specific IgA protease recognition sequence S-R-P-P-S-P, were cleaved by
incubation of the ion metal affmity chromatography column with 0.1 p@g/ml
IgA protease (Boehringer Mannheim, Mannheim, Federal Republic of Ocr
many) for 10 h at 37Â°C.Finally, the cleaved MIA protein was eluted into PBS
(pH 7.35). In parallel, the parental pOE 40 vector without a MIA insert was
processed identically, including the IgA protease step; the PBS eluate was used
as a control for treatment of melanoma cells in tissue culture experiments.
Foreukaryoticexpression,the huMIA-7cDNA was ligated into the EcoRI
site of the vector pCMX pLi (20) and transiently transfected into PA-i sc9il7
cells using the calcium phosphate precipitation method (13). After the trans
fection, cells were washed three times in PBS and incubated for an additional
48 h in serum-free minimum essential medium. The supernatant was collected
and cleared from cellular debris by centrifugation (10 min at 2500 X g). As a
control, the empty pCMX-pLi vector was transfected and processed precisely
as the MIA-expression construct.
RESULTS
Purification of MIA from HTZ-19 Supernatants. Purification of
MIA from serum-free supernatants of HTZ-i9 cells is described in
detail elsewhere (7, 8). Fractions from Biogel P-10 gel column chro
matography with the highest specific inhibitory activity were pooled
(designated P-10 pool) and separated further by rpHPLC. The main
activity was eluted from the rpHPLC column in fraction 42 and shown
to contain a single protein with a Mr 11,000. This protein was
designated MIA. Growth inhibition was accompanied by a change in
cytomorphology, resulting in a compact, rounded-up and less adherent
phenotype (Fig. i). However, exposure to MIA is not cytotoxic, as
demonstrated by trypan blue exclusion and reversal of growth inhi
bition after removal of MIA (data not shown).
Molecular Cloning ofMIA (8). After purification and preliminary
functional characterization of the Mr 1 1,000 MIA protein, direct
@2term@@alsequencing was performed. To obtain internal peptide
fragments, the protein was reduced, carboxymethylated, and digested
with trypsin and Asp-N-protease, respectively. Finally, fragments
were separated by rpHPLC and microsequenced by Edman degrada
tion. Ten partially overlapping peptide sequences were obtained coy
ering a total of 89 amino acids, as shown in Fig. 2a. Two degenerated
oligonucleotides were synthesized, matching predicted amino acid
codons from the NH2-terminal and COOH-terminal peptides (Fig.
2a). Using these primers, a cDNA fragment was amplified by reverse
transcriptase-polymerase chain reaction from HTZ-19 RNA. This
fragment served as a probe to screen 3 X 10@plaques of a Agtii
cDNA library from the HTZ-19 cell line, resulting in 10 independent
overlapping cDNA clones. Two of these clones covered the entire
open reading frame [Fig. 2, a (top) and c]. We further used the longest
human cDNA clone huMIA-7 to screen 3 X i0@ plaques of a com
mercially available murine embryo cDNA library (day 13, Ref. 5;
Novagene) resulting in five overlapping cDNA clones, two of which
covered the complete murine open reading frame (Fig. 2a, bottom).
The human and murine protein sequences are aligned in Fig. 2a. A
search by Fasta through the EMBL data base (peptide search word
size, 2; sequence search wordsize, 6; Ref. 21) yielded no significant
homology to any other known protein or nucleic acid sequence. A
comparison between the open reading frame predicted from the hu
man cDNA and the sequence information obtained from the NH2-
terminal peptide sequence of the originally purified Mr 11,000 protein
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nomas (HTZ-318 and HTZ-320) and, to a lesser extent, in one glioma
i%d@celline(HTZ-243;Fig.3b).Unfortunately,neithertheantiserumnor
the purified immunoglobulin fraction neutralized the growth inhibi
tory effect of MIA.
Expression of Recombinant MIA Protein. We next aimed to
prove that the cloned gene codes for a protein with the identical
biological activity as the originally purified MIA protein. Therefore,
we cloned the MIA cDNA into the prokaryotic expression vector pOE
40 (Quiagen, Chatsworth, CA). To find out whether posttranslational
modifications are required for biological activity, we also constructed
a eukaryotic vector using the cytomegalovirus expression plasmid
pCMX-pLl (20). Recombinant bacterial MIA was expressed as a
fusion protein with histidine-tagged DHFR (23) and purified by ion
metal affinity chromatography. The fusion protein was expressed
B abundantly in E. coli, mostly as inclusion bodies. However, a fraction
of the protein was soluble and could be cleaved while attached to the
chromatography column using the IgA protease. Finally a single M1
11,000 MIA protein was eluted from the column at a purity greater
than 95%, as verified by silver-stained SDS-PAGE (Fig. 4). For
eukaryotic MIA expression, the plasmid pCMXpL1-MIA was tran
siently expressed in the teratocarcinoma cell line PA-i (13). PA-i
cells were chosen since they are efficiently transfected by the calcium
phosphate technique and express no endogenous MIA-related mR
NAs, as verified by Northern hybridizations (data not shown).
Serum-free tissue culture supernatants were collected 48 h after
transfections and tested for secreted MIA activity. SDS-PAGE
analysis revealed that an Mr 11,000 protein is secreted into the
tissue culture supernatant by pCMXpL1-MIA transfected PA-i
cells and is absent in control transfections using the empty vector
pCMXpL1 (Fig. 4). Western blot analysis revealed that the pro
karyotic recombinant MIA reacted with the MIA-specific anti
serum (Fig. 3b).
Then we tested the biological activity of the recombinant MIA
proteins. As shown in Table 1, both the prokaryotic and eukaryotic
recombinant MIA inhibited [3H]thymidine incorporation of HTZ-19
melanoma and HTZ-243 glioma cells and stimulated H-36 fibroblasts.
No alteration of [3H]thymidine incorporation was observed with
HTZ-17 glioblastoma cells. Thus, the effects of recombinant MIA
proteins are identical to those observed using the original protein from
HTZ-19 supernatants. The prokaryotic MIA protein was approxi
mately as active as the originally purified MIA protein (approximately
50% inhibitory dose: 20â€”30 ng/ml) and demonstrated a clear dose
response relationship when tested upon Mel Im and HTZ-19 mela
noma cells (Fig. 5a).
To confirm the data we obtained from [3H]thymidine incorporation,
we measured cell growth curves using HTZ-19 cells and, in addition,
an independent human melanoma cell line, Mel Im. Duplicate samples
were seeded into 6 well dishes and treated with purified recombinant
prokaryotic MIA and supernatant containing MIA protein from eu
karyotic expression. As controls, cells were treated with equivalent
amounts of purified supernatants obtained from empty expresson
vectors (see â€œMaterialsand Methodsâ€•).The effects were quantified
as cell growth curves by counting cells daily. As demonstrated in
Fig. 5, b and C, the Mel Im cells are extremely sensitive to MIA
and are rapidly growth arrested between days 2 and 3 at a cell number
90% below control cultures. HTZ-i9 cells are less sensitive to MIA;
however, a significant reduction in cell number, approximately 60%,
was found after 7 days.
DISCUSSION
Evidence has accumulated indicating that proliferation and invasion
of tumor cells are regulated by a complex network of positive and
Fig. 1. Morphology of HTZ-19 cells treated with purified MIA. Cells treated with
HPLC-purifiedMIA(A)in comparisonto untreatedcells(B)4 h afterstartof treatment.
MIA-treated cells are beginning to roundup.
revealed that human MIA is translated as a 131-amino acid precursor
molecule that is processed into a mature 107-amino acid protein after
cleavage of a 24-amino acid secretion signal. The site of proteolytic
cleavage is indicated by an arrow in Fig. 2a. These 24 amino acids are
extremely hydrophobic and are cleaved after the amino acid residues
Arg-Gly, features that are well known from other eukaryotic secretion
signals (22). The murine secretion signal is slightly shorter than the
human sequence and differs in 10 of 23 residues. However, the key
features are well conserved, i.e., hydrophobicity and a strongly
charged arginine at the second-last residue.
A hydrophobicity profile using the Kyte-Doolittle algorithm re
vealed four hydrophobic domains in addition to the hydrophobic
secretion signal (Fig. 2b). Although the mature murine peptide Se
quence differs in 13 of 107 amino acids, the overall structure of
hydrophobic and hydrophilic domains is highly conserved. Inspection
of the sequences further revealed four conserved cysteine residues
(Fig. 2a, asterisks), which are likely to be relevant for the correct
three-dimensional folding of the protein.
Expression of MIA mRNA and Protein. We then examined the
expression of MIA mRNA in various cell lines of different histoge
netic origin. A single mRNA of â€”750 bases is detected in every
melanoma cell line (n = 8) analyzed, and in 1 of 5 glioma cell lines
(Fig. 2a). No message is found in human lymphomononuclear cells
(n 5) or in fibroblasts (n = 2). Thus, MIA appears to be frequently
expressed in neuroectodermal tumor cell lines. In addition, no MIA
mRNA expression in normal tissues was detected using a mouse
multitissue Northern blot (data not shown).
A polyclonal rabbit antiserum, produced by repeated immunization
with a MIA-specific NH2-terminal 15-mer peptide coupled to bovine
serum albumin, recognizes MIA protein throughout all purification
steps of HTZ-19 tissue culture supernatants. M1A protein-related
immunoreactivity is also detected in supernatants of two other mela
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Fig. 2. Molecular cloning of MIA. A, comparison
of the amino acid sequenceof human(top) and
mouse (bottom) MIA. Conserved cysteines are
marked by an asterisk, sequences used for primer
synthesis by upper linings. (â€”--), peptide se
quences obtained from microsequencing. Arrow,
cleavage site of signal protease B, Kyte-Doolittle
hydrophobicity analysis of the MIA protein (32). A
strong hydrophobic secretion signal is followed by
additional four hydrophobic domains. C, cDNA se
quence of human MIA.Â°
a +
human Mia 1 MARSLVCLGVIILLSAFSGPGVRGG?MpKLADRKLcAD@ECsxpzgM@vA 50
l.:lllll::lI.IlIJ:
murine Mia 1 MVWSPVLLG.@ 49
* *
human Mia 5 1 LQDYMAPDCRPLTIHRGgyVYVF ?KLKGRGRLFWGGSVQGDYYGDLAARL 100
III :111111 II1.11 IIII@ 111111 IIIIII II111:11 IIIIII
murine Mia 50 LQDYVAPDCRPLTIYRGQVVYVFSKL1@GRGRLFWGGSVQGGTYGDLAA@L99
*
human Mia 101 GYFPSSIVREDQTLKPGKVDVKTDKWDFYqQ131
lllIIiIllll .
murine Mia 100 GYFPSSIVREDLNSKPGRIDMKTDQ1IDFYCQ 130
b
4
3
2
1
0
-1
-2
-3
C
125 1318@
MIA
ACG AVG GCC CGG
Met Ala Mg
ocT GTG GCC CTT
Ala Val Ala Leu
ATF CAC COG 0CC
fle His Mg Gly
CCA GCA CCC CCT TGC TCA CTC TCT TGC TCA CAG TCC
49 TCC CTG GTG TGC CTF GOT GTC ATC ATC TTG CTG PCT CCC @1Â°1'C7 C GGA
4 Ser Leu Val Cys Leu Gly Val fle fle Leu Leu Ser Ala Phe Ser Gly
97 CCT GOT GTC AGG COT GOT CCT AVG CCC AAG CTG OCT GAC COG AAG CTG
20 Pro Gly Va! Mg Gly Gly Pro Met Pro Lys Leu Ala Asp Mg Lys Leu
145 TGT GCG GAC CAG
36 Cys Ala Asp Gin
193 CAG GAC TAC ATG
52 GIn Asp Tyr Met
385 CCT CCC AAA GTC
116 Pro Gly Lys Val
433 VGA GCT CAG CCT
132 End
GAG TGC
Gin Cys
CCC CCC
Ala Pro
AGC CAC CCT ATC TCC AVG
Ser His Pro ile Ser Met
GAC TGC CGA @FCCTG ACC
Asp Cys Arg Phe Leu Thr
GAT GTG AAG ACA GAC
Asp Val Lys Thr Asp
ACC @T GOC CCT GCC
241 CAA GTG GVG TAT
68 GIn Val Val Tyr
289 TOG GGA CCC AGC
84 Trp Gly Gly Ser
GTC TTC
Val Phe
01Â°F CAG
Vat Gin
TCC AAG CTG AAG CCC CGT
5cr Lys Leu Lys Gly Mg
OGA GAT TAC TAT GGA GAT
Gly Asp Tyr Tyr Gly Asp
GOG COG CTC TTC
Gly Mg Leu Phe
CTG CCV OCT CCC
Leu Ala Ala Mg
337 CTG CCC TAT TFC CCC AGT AGC A11@ GTC CGA GAG GAC CAG ACC CTG AAA
100 Leu Gly Tyr Phe Pro 5cr 5cr fle Val Mg Clii Asp Gin Thr Leu Lys
AAA TOG OAT â€˜FTC TAC TGC CAG
Lys Tip Asp Phe Tyr Cys Gin
Previous analyses revealed that HTZ-19 cells were stimulated in an
autocrine fashion by PDGF and bFGF and, thus, were able to grow
independent of exogenous growth factors in serum-free medium (5,
6). We were able to further identify several other proteins secreted by
HTZ-19 cells that are implicated in regulation of tumor progression
and invasion. Among these factors were TGF-(31, tissue inhibitor of
metalloproteinases (7, 26), diazepam-binding inhibitor (27), and a
fourth, thus far uncharacterized, protein MIA (8), conferring growth
inhibition upon melanoma cells. These data indicated that both tumor
negative growth regulatory signal molecules. Extended studies of
malignant melanomas have shown that autocrine factors produced by
tumor cells of advanced progression include at least MGSA and
bFGF, which are not or only faintly expressed in normal melanocytes
(1, 24, 25). It was, therefore, intriguing to study growth regulatory
proteins secreted by the human melanoma cell line HTZ-19 that were
derived from a tumor with exceptionally slow progression in vivo (8).
8 The cDNA sequence has been submitted to the EMBL Data Library under the
accession number X 75450.
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growth regulatory factor. It is intriguing that this WA-positive cell
â€” 4.4 line HTZ-243 was also derived from a tumor with exceptionally slow
4 clinicalprogressionsimilar to themelanomacell line HTZ-19. All cell
2. lines that were sensitive to growth inhibition by MIA also expressed
â€” 1.4 MIA mRNA and exhibited dose-dependent response curves (data not
presented). However, there was no direct correlation between the level
0.24 of MIA expression and the extent of growth inhibition in vitro. A
â€” number of melanoma cell lines that we analyzed were very sensitive
to the effect of MIA, although derived from highly malignant and
fi-actin rapidly progressing tumors. Taken together, these data indicate that
cellular signal perception mediated by a receptor and intracellular
signal transduction may modulate the effects of MIA. Earlier exper
iments using fluorescence-activated cell sorter analysis indicated a
specific effect on cell cycle regulation. We observed a prolongation of
G1 to S transition, a prolongation of S, and a cell cycle arrest in 02
(30). This is interesting because MIA differs in this respect from most
other growth factors including TGF-@3,which arrests the cell cycle at
01 (31). MIA is not cytotoxic as verified by trypan blue exclusion
assays. This observation is rather similar to growth regulatory effects
of TGF-f3, where direct cytotoxic effects on cells are not observed.
The expression pattern and the physiological role of MIA in normal
tissues remain to be determined. We were unable to identify signifi
cant levels of MIA mRNA on a Northern blot of 16 different normal
murine tissues, including skin and brain, indicating that MIA is either
absent or expressed at very low levels in adult tissues. However, we
were able to isolate five independent cDNA clones by screening
3 X i05 plaques of a total mouse embryo (day 13.5) cDNA library.
Thus, MIA is expressed at high levels during mid-gestation and may,
therefore, have a function in regulation of embryonic cell growth and
morphogenesis.
Several lines of evidence indicate that MIA is secreted as a small
globular protein stabilized by two intramolecular disulfide bonds; all
four cysteine residues are conserved between the human and murine
sequence, and the overall structure of hydrophobic and hydropilic
domains is identical. Reduction of the disulfide bonds results in a
slower electrophoretic mobility (data not presented) and in a highly
insoluble protein, probably due to dislocation of the many hydropho
bic residues to the protein surface. The latter observation was a serious
obstacle for production of recombinant MIA protein in bacteria.
Consequently, we expressed MIA as a fusion protein with dihydro
folate reductase and renatured the protein at low concentrations after
proteolytic cleavage. Interestingly, when we purified MIA using a
COOH-terminal histidine tag that was positioned next to the cysteine
at amino acid position 130, we obtained a protein that was totally
inactive in growth inhibition assays (data not shown). This observa
Table 1 Biological activity of recombinant MIAproteinAntiproliferative
effects of purified and recombinant huMIA protein. Data, percentage
mean values of [3H]thymidine incorporation (rpm) of treated cells (MIA@1@,MIAHp@)relative
to untreated, or treated cells (recombinant MIA, MlA,,@,and MIA.,,m) compared
to control treated cells (see Fig. 5a, b) including SD. Data points are means ofriplicates;Stud nt's
t test wasapplied.Cell
linesâ€• rMIA,,,b rM1A.@ MIAHPLCMIA@10HTZ-19(M )
@7Ã·3d 12@4d 11@8d
HTZ-243(MG) 40.oÂ±3e 77Â±11 70Â±1185Â±8HTZ-17(MG)
93Â±5 94Â±9 nd. 108Â±2
H-36(FB) 154@12g 164@18g 88Â±21 132Â±26â€•
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Fig. 4. Recombinant expression of MIA in prokaryotic and eukaryotic systems. SDS
PAGE,15%,silverstained,showingexpressionofhumanMIAinE.coliasDHFR-fusion
protein, using the vector pQE-40 before (Lane 1) and after (Lane 2) IPTG induction, as
well as affinity-purifiedMIA after cleavagewith IgA protease(Lane 3). Eukaryotic
expression: supernatants of cells transfected with the empty vector pCMX-pLl as control
(Lane 4) and the vector containing the complete MIA cDNA sequence (Lane 5).
a MM, malignant melanoma; MG, malignant glioma; FB, human fibroblasts.
rM@,, recombinant MIA.
C rMIA.@,m, recombin MIA protein.
d Significant inhibition (P < 0.001) compared to individual controls.
e Significant inhibition (P < 0.01) comparedto individual controls.
â€˜@Significantinhibition (P < 0.05) compared to individual controls.
gSignificantstimulation(P<0.01)comparedtoindividualcontrols.
h Significant stimulation (P < 0.05) compared to individual controls.
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Fig. 3. Expression pattern of MIA mRNA and protein. A, Northern blot analysis of
MIA mRNA expression in the cell line Mel Im (Lane 1; human malignant melanoma);
peripheral blood mononuclear cells (Lane 2); HTZ-298 (Lane 3) and HTZ-262 (Lane 4)
(glioblastoma multiforme); HTZ-243(Lane 5; human malignant astrocytoma, WHO grade
III);H-36(Lane6; normalhumanskinfibroblasts);HTZ-17(Lane7)andHTZ-146(Lane
8) (glioblastomamultiforme);HTZ-1014(Lane 9); HTZ-1004(Lane 10); G-361(Lane
11); SK-Mel 3 (Lane 12); HTZ-320(Lane13); HTZ-318(Lane 14); andHTZ-19 (Lane
15)(human malignant melanomas). (-*), MIA signal . ACtincontrols are displayed below.
B, Western Blots usingpolyclonal anti-MIA-peptidespecific antiserum:rpHPLC-purified
MIA (Lane I), P.10 pool (Lane 2), HTZ-19 (Lane 3), HTZ-320 (Lane 4), HTZ-318
(l@ane 5), HTZ-243 (Lane 6), and HTZ-17 (Lane 7) supernatants and prokaryotic
expressed MIA fusion protein (Lane 8).
1 2 3 4 5
growth-promoting effects and negative growth-regulatory mecha
nisms are relevant in this melanoma model.
Here we report on the molecular cloning of the novel growth
regulatory protein, M1A, which has no homology to other known
proteins. MIA seems to be widely expressed in malignant melanomas
but not in normal fibroblasts or lymphocytes. We purified MIA as an
Mr 1 1,000 protein secreted by melanoma cells and isolated the cor
responding human and murine cDNAs. Prokaryotic and eukaryotic
expression strategies are described substantiating the function of MIA
as a potent negative growth factor and as a potential future therapeutic
agent.
Our studies of MIA expression using Northern and Western blot
analyses revealed that MIA is widely expressed at variable levels in
malignant melanoma cells. We found MIA mRNA in every melanoma
cell line tested thus far. Interestingly, we also observed MIA expres
sion in one glioma cell line (HTZ-243; Refs. 28 and 29) raising the
possibility that MIA is a more generally expressed neuroectodermal
kDa
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(Munich)for the melanomacell line Mel Im. We dedicatethis paperto the
chemist Wilhelm Neumann.
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Fig.5. Biologicalactivityof recombinantMIA
protein. A, dose-response curves of the melanoma
cell lines HTZ-19 (â€¢)and Mel Im (0. Cells were
treated for 5 days with the indicated doses of
prokaryotic expressed MIA; relative growth was
determined by counting cells treated with recom
binant MIA compared to controls treated with
identically purified protein from E. coli bearing
the empty vector pOE-40. Protein concentrations
were estimated by comparing the intensity of sil
ver staining of MIA with standard proteins in
SDS-gels. B, cell growth curves of HTZ-19 and
MelImaftertreatmentwithrecombinanthuMIA,
expressed in E. coli. Controlswere treatedwith
identically purified protein from E. coli bearing
the empty vector pQE-40 (relative growth is given
in a percentage Â±SD). C, cell growth curve of
Mel Im after treatmentwith supernatatantscon
taming eukaryotic expressed rekombinant huMlA.
Controls were treated with supematants of the
PA-i cellstransfectedwiththeemptyvector(rel
ative growth is given in percentage Â±SD).
ng/mI MIA
0 controlMelPm
D treatedMelPm
0 controlHTZ-19
D t@@@tdHTZ-19
tion further points to an important role of the intramolecular cysteine
bonds in correct protein folding and function.
Our bacterial expression strategy yielded MIA protein with a purity
greater than 95%, as assessed by silver-stained polyacrylamide gels.
Probably due to the higher purity, the bacterially purified MIA protein
was slightly more active than protein recovered from transient eu
karyotic expression and as active as the original protein purified from
HTZ-19 supematants. Both recombinant proteins were of identical
size, as estimated by polyacrylamide gel electrophoresis. These data
indicate that MIA function does not require further posttranslational
modifications,suchasglycosylation.We alsofoundthatthebacteri
ally expressed MIA protein refolded efficiently in a phosphate buffer
after proteolytic cleavage from the fusion protein. Therefore, the
expression strategy we describe in this report yields physiologically
active MIA protein at a purity that will be required for potential
application in vivo.
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